Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 331 Records) |
| Query Trace: Neoplasms and UGT1A1[original query] |
|---|
| Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer. Scientific reports 2022 9 12 (1): 15574. Irisawa Ai, Takeno Misaki, Watanabe Kazuo, Takahashi Hideaki, Mitsunaga Shuichi, Ikeda Masafu |
| Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 2022 Aug 8 (1): 98. Rugo Hope S, Tolaney Sara M, Loirat Delphine, Punie Kevin, Bardia Aditya, Hurvitz Sara A, O'Shaughnessy Joyce, Cortés Javier, Diéras Véronique, Carey Lisa A, Gianni Luca, Piccart Martine J, Loibl Sibylle, Goldenberg David M, Hong Quan, Olivo Martin, Itri Loretta M, Kalinsky Kev |
| Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study. Drugs in R&D 2022 Aug . Umemiya Maki, Inayama Yoshihide, Nakatani Eiji, Ito Kenta, Tsuji Mitsuru, Yoshida Teruki, Yu Sae, Gou Rei, Horikawa Naoki, Tani Hirohiko, Kosaka Ken |
| Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis. Clinical and translational science 2022 May . Atasilp Chalirmporn, Biswas Mohitosh, Jinda Pimonpan, Nuntharadthanaphong Nutthan, Rachanakul Jiratha, Hongkaew Yaowaluck, Vanwong Natchaya, Saokaew Surasak, Sukasem Chonlaph |
| The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. International journal of clinical oncology 2022 5 27 (8): 1331-1339. Satake Tomoyuki, Morizane Chigusa, Maruki Yuta, Ohba Akihiro, Nagashio Yoshikuni, Kondo Shunsuke, Hijioka Susumu, Ueno Hideki, Okusaka Taku |
| Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to UGT1A1 Polymorphism: Compared to Liver Metastasis-Only, and Lung Metastasis-Only. Cancer management and research 2022 5 14 1541-1549. Li Ching-Chun, Chang Tsung-Kun, Chen Yen-Cheng, Tsai Hsiang-Lin, Huang Ching-Wen, Su Wei-Chih, Ma Cheng-Jen, Yin Tzu-Chieh, Chen Po-Jung, Wang Jaw-Yu |
| Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2022 3 25 (3): 137-146. Li Qian, Sun Tao, Zhang Hua, Liu Wei, Xiao Yu, Sun Hongqi, Yin Wencheng, Yao Yanhong, Gu Yangchun, Liu Yan'e, Yi Fumei, Wang Qiqi, Yu Jinyu, Cao Baoshan, Liang |
| UGT1A1 Gene Polymorphism Contributes as a Risk Factor for Lung Cancer: A Pilot Study with Patients from the Amazon. Genes 2022 3 13 (3): . Pereira Esdras E B, Leitão Luciana P C, Andrade Roberta B, Modesto Antônio A C, Fernandes Bruno M, Burbano Rommel M R, Assumpção Paulo P, Fernandes Marianne R, Guerreiro João F, Santos Sidney E B Dos, Santos Ney P C D |
| Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia. JAMA network open 2022 12 5 (12): e2248803. Yang Wenjian, Karol Seth E, Hoshitsuki Keito, Lee Shawn, Larsen Eric C, Winick Naomi, Carroll William L, Loh Mignon L, Raetz Elizabeth A, Hunger Stephen P, Winter Stuart S, Dunsmore Kimberly P, Devidas Meenakshi, Relling Mary V, Yang Jun |
| Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan. European journal of human genetics : EJHG 2022 11 . Hulshof Emma C, Deenen Maarten J, Nijenhuis Marga, Soree Bianca, de Boer-Veger Nienke J, Buunk Anne-Marie, Houwink Elisa J F, Risselada Arne, Rongen Gerard A P J M, van Schaik Ron H N, Touw Daan J, van der Weide Jan, van Westrhenen Roos, Deneer Vera H M, Guchelaar Henk-Jan, Swen Jesse |
| Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. Cancer medicine 2022 10 . Kanesada Kou, Tsunedomi Ryouichi, Hazama Shoichi, Ogihara Hiroyuki, Hamamoto Yoshihiko, Shindo Yoshitaro, Matsui Hiroto, Tokumitsu Yukio, Yoshida Shin, Iida Michihisa, Suzuki Nobuaki, Takeda Shigeru, Ioka Tatsuya, Nagano Hiroa |
| Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain. Pharmaceutics 2022 10 14 (10): . Bravo-Gómez Adrián, Salvador-Martín Sara, Zapata-Cobo Paula, Sanjurjo-Sáez María, López-Fernández Luis Andr |
| Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 2022 Jul 46 (4): 224-233. Miarons Marta, Riera Pau, García-Gil Sara, Gutiérrez-Nicolás Fernan |
| The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients. Genomics & informatics 2022 Sep 20 (3): e29. Lee Choong-Kun, Chon Hong Jae, Kwon Woo Sun, Ban Hyo-Jeong, Kim Sang Cheol, Kim Hyunwook, Jeung Hei-Cheul, Chung Jimyung, Rha Sun You |
| Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study. Thoracic cancer 2023 9 . Hiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, Takaya Ikeda, Seiji Nagashima, Kazumasa Akagi, Sawana Ono, Yasuhiro Umeyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Yasushi Hisamatsu, Ryotaro Morinaga, Ryuta Tagawa, Ryosuke Ogata, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Katsumi Nakatomi, Fumiko Hayashi, Nanae Sugasaki, Akitoshi Kinoshita, Hiroshi Muk |
| Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1. Clinical pharmacokinetics 2023 9 . Mirjam de With, Leni van Doorn, Esmay Kloet, Anne van Veggel, Maja Matic, Micha J de Neijs, Esther Oomen-de Hoop, Esther van Meerten, Ron H N van Schaik, Ron H J Mathijssen, Sander Bi |
| Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer. Genetic testing and molecular biomarkers 2023 5 27 (5): 133-141. Zineb Aoullay, Andrew Smith, Meriem Slaoui, Ihssane El Bouchikhi, Hassan Ghazal, Najib Al Idrissi, Bouchra Meddah, Kara L Lynch, Yahia Cherrah, Alan H B |
| A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of gastrointestinal oncology 2023 5 14 (2): 663-675. Shigeo Higami, Masaya Mukai, Daiki Yokoyama, Syuji Uda, Rin Abe, Nana Mamuro, Kyoko Kishima, Sayuri Hasegawa, Takayuki Tajima, Eiji Nomura, Hiroyasu Makuuc |
| UGT1A1 genotype-guided irinotecan dosing during neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A prospective analysis of SN-38 concentration. International journal of cancer 2023 12 . Pei-Cheng Jiang, Shuo-Wen Wang, Chao Li, Jin Fan, Ji Z |
| Direct Comparative Analysis of a Pharmacogenomics Panel with PacBio Hifi Long-Read and Illumina Short-Read Sequencing. Journal of personalized medicine 2023 12 13 (12): . David Barthélémy, Elodie Belmonte, Laurie Di Pilla, Claire Bardel, Eve Duport, Veronique Gautier, Léa Pay |
| Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in BRAF-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single-Center Observational Study. Medicina (Kaunas, Lithuania) 2023 12 59 (12): . Hsiang-Lin Tsai, Ching-Wen Huang, Yen-Cheng Chen, Wei-Chih Su, Tsung-Kun Chang, Po-Jung Chen, Ching-Chun Li, Yu-Tang Chang, Jaw-Yuan Wa |
| A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC? Cancer chemotherapy and pharmacology 2023 11 . Angeline Ginzac, Emilie Thivat, Caroline Petorin, Damien Richard, Pauline Herviou, Ioana Molnar, Hervé Devaud, Isabelle Creveaux, Florent Ferrer, Nicolas Authier, Marine Jary, Denis Pezet, Xavier Duran |
| Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group. Journal of experimental & clinical cancer research : CR 2023 1 42 (1): 21. Junk Stefanie V, Schaeffeler Elke, Zimmermann Martin, Möricke Anja, Beier Rita, Schütte Peter, Fedders Birthe, Alten Julia, Hinze Laura, Klein Norman, Kulozik Andreas, Muckenthaler Martina U, Koehler Rolf, Borkhardt Arndt, Vijayakrishnan Jayaram, Ellinghaus David, Forster Michael, Franke Andre, Wintering Astrid, Kratz Christian P, Schrappe Martin, Schwab Matthias, Houlston Richard S, Cario Gunnar, Stanulla Mart |
| ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer. Pharmaceutics 2024 9 16 (9): . Andrés Barba, Laura López-Vilaró, Malena Ferre, Margarita Majem, Sergio Martinez-Recio, Olga Bell, María J Arranz, Juliana Salazar, Ivana Sulliv |
| Meta-analysis revisiting the influence of UGT1A1*28 and UGT1A1*6 on irinotecan safety in colorectal cancer patients. Pharmacogenomics 2024 8 1-10. Cuc Thi Thu Nguyen, Nguyen Thi Minh Thuy, Phung Thanh Huo |
| UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan. Cancer medicine 2024 8 13 (16): e70096. Megan H Wong, Veronica C Jones, Wai Yu, Linda D Bosserman, Sayeh M Lavasani, Niki Patel, Mina S Sedrak, Daphne B Stewart, James R Waisman, Yuan Yuan, Joanne E Mortim |
| Association of genetic variants in soy isoflavones metabolism-related genes with decreased lung cancer risk. Gene 2024 6 927 148732. Dongming Xie, Yujie Pan, Jinbin Chen, Chun Mao, Zhi Li, Fuman Qiu, Lei Yang, Yibin Deng, Jiachun |
| Risk Factors for Adverse Events of Nanoliposomal Irinotecan Plus 5-Fluorouracil and L-leucovorin. Cancer diagnosis & prognosis 2024 5 4 (3): 244-249. Takahiro Ito, Manabu Suno, Hideki Egawa, Serina Hiraoka, Kohei Kamei, Shohei Sano, Reiko Ashida, Manabu Kawai, Kazuo Matsuba |
| Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors. Clinical pharmacokinetics 2024 4 . Abhishek G Sathe, Indrajeet Singh, Pratap Singh, Paul M Diderichsen, Xiaohui Wang, Peter Chang, Atiya Taqui, See Phan, Sandhya Girish, Ahmed A Othm |
| Assessing the Occurrence and Influence of Cancer Chemotherapy-Related Pharmacogenetic Alleles in the Chilean Population. Pharmaceutics 2024 4 16 (4): . Gareth I Owen, Miguel Cordova-Delgado, Bernabé I Bustos, Leslie C Cerpa, Pamela Gonzalez, Sebastián Morales-Pison, Benjamín Garcia-Bloj, Marcelo Garrido, Juan Francisco Miquel, Luis A Quiñon |
- Page last reviewed:Feb 1, 2024
- Content source: